|
1
|
Messerschmitt PJ, Garcia RM, Abdul-Karim
FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop
Surg. 17:515–527. 2009.PubMed/NCBI
|
|
2
|
Shen H and Laird PW: Interplay between the
cancer genome and epigenome. Cell. 153:38–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kristensen LS, Nielsen HM and Hansen LL:
Epigenetics and cancer treatment. Eur J Pharmacol. 625:131–142.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferguson LR, Tatham AL, Lin Z and Denny
WA: Epigenetic regulation of gene expression as an anticancer drug
target. Curr Cancer Drug Targets. 11:199–212. 2011. View Article : Google Scholar
|
|
5
|
Rogawski MA and Löscher W: The
neurobiology of antiepileptic drugs. Nat Rev Neurosci. 5:553–564.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bialer M: Why are antiepileptic drugs used
for nonepileptic conditions? Epilepsia. 53(Suppl 7): S26–S33. 2012.
View Article : Google Scholar
|
|
7
|
Dickinson M, Johnstone RW and Prince HM:
Histone deacetylase inhibitors: Potential targets responsible for
their anticancer effect. Invest New Drugs. 28(Suppl 1): S3–S20.
2010. View Article : Google Scholar
|
|
8
|
Tan KB, Harrop J, Reddy M, Young P,
Terrett J, Emery J, Moore G and Truneh A: Characterization of a
novel TNF-like ligand and recently described TNF ligand and TNF
receptor superfamily genes and their constitutive and inducible
expression in hematopoietic and non-hematopoietic cells. Gene.
204:35–46. 1997. View Article : Google Scholar
|
|
9
|
Zhai Y, Ni J, Jiang GW, et al: VEGI, a
novel cytokine of the tumor necrosis factor family, is an
angiogenesis inhibitor that suppresses the growth of colon
carcinomas in vivo. FASEB J. 13:181–189. 1999.PubMed/NCBI
|
|
10
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chew LJ, Pan H, Yu J, Tian S, Huang WQ,
Zhang JY, Pang S and Li LY: A novel secreted splice variant of
vascular endothelial cell growth inhibitor. FASEB J. 16:742–744.
2002.PubMed/NCBI
|
|
12
|
Migone TS, Zhang J, Luo X, Zhuang L, Chen
C, Hu B, Hong JS, Perry JW, Chen S-F and Zhou JXH: TL1A is a
TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell
costimulator. Immunity. 16:479–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grimaldo S, Tian F and Li LY:
Sensitization of endothelial cells to VEGI-induced apoptosis by
inhibiting the NF-kappaB pathway. Apoptosis. 14:788–795. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ge Z, Sanders AJ, Ye L and Jiang WG:
Aberrant expression and function of death receptor-3 and death
decoy receptor-3 in human cancer. Exp Ther Med. 2:167–172.
2011.PubMed/NCBI
|
|
15
|
Liang PH, Tian F, Lu Y, Duan B, Stolz DB
and Li LY: Vascular endothelial growth inhibitor (VEGI; TNFSF15)
inhibits bone marrow-derived endothelial progenitor cell
incorporation into Lewis lung carcinoma tumors. Angiogenesis.
14:61–68. 2011. View Article : Google Scholar :
|
|
16
|
Chinnaiyan AM, O’Rourke K, Yu GL, Lyons
RH, Garg M, Duan DR, Xing L, Gentz R, Ni J and Dixit VM: Signal
transduction by DR3, a death domain-containing receptor related to
TNFR-1 and CD95. Science. 274:990–992. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL
and Lin WW: Soluble decoy receptor 3 induces angiogenesis by
neutralization of TL1A, a cytokine belonging to tumor necrosis
factor superfamily and exhibiting angiostatic action. Cancer Res.
64:1122–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hou W, Medynski D, Wu S, Lin X and Li LY:
VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor
vascular endothelial cells and suppresses tumor growth. Clin Cancer
Res. 11:5595–5602. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z and Li LY: TNFSF15 modulates
neovascularization and inflammation. Cancer Microenviron.
5:237–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao Q, Hsu CY, Chen H, Ma X, Xu J and Lee
JM: Characterization of cis-regulatory elements of the vascular
endothelial growth inhibitor gene promoter. Biochem J. 388:913–920.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marks PA and Xu WS: Histone deacetylase
inhibitors: Potential in cancer therapy. J Cell Biochem.
107:600–608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bai C, Connolly B, Metzker ML, et al:
Overexpression of M68/DcR3 in human gastrointestinal tract tumors
independent of gene amplification and its location in a four-gene
cluster. Proc Natl Acad Sci USA. 97:1230–1235. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahama Y, Yamada Y, Emoto K, Fujimoto H,
Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T and Nakajima Y: The
prognostic significance of overexpression of the decoy receptor for
Fas ligand (DcR3) in patients with gastric carcinomas. Gastric
Cancer. 5:61–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ge Z, Sanders AJ, Ye L, Wang Y and Jiang
WG: Expression of death decoy receptor-3 (DcR3) in human breast
cancer and its functional effects on breast cancer cells in vitro.
J Exp Ther Oncol. 9:109–118. 2011.PubMed/NCBI
|
|
25
|
Zong L, Chen P and Wang DX: Death decoy
receptor overexpression and increased malignancy risk in colorectal
cancer. World J Gastroenterol. 20:4440–4445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qian DZ, Kachhap SK, Collis SJ, Verheul
HM, Carducci MA, Atadja P and Pili R: Class II histone deacetylases
are associated with VHL-independent regulation of hypoxia-inducible
factor 1 alpha. Cancer Res. 66:8814–8821. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kong X, Lin Z, Liang D, Fath D, Sang N and
Caro J: Histone deacetylase inhibitors induce VHL and
ubiquitin-independent proteasomal degradation of hypoxia-inducible
factor 1alpha. Mol Cell Biol. 26:2019–2028. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang FW, Que L, Wu M, Wang ZL and Sun J:
Effects of trichostatin A on HIF-1α and VEGF expression in human
tongue squamous cell carcinoma cells in vitro. Oncol Rep.
28:193–199. 2012.PubMed/NCBI
|
|
29
|
Zhao Y, Yu D, Wu H, Liu H, Zhou H, Gu R,
Zhang R, Zhang S and Wu G: Anticancer activity of SAHA, a potent
histone deacetylase inhibitor, in NCI-H460 human large-cell lung
carcinoma cells in vitro and in vivo. Int J Oncol. 44:451–458.
2014.
|
|
30
|
Xiao T, Fan JK, Huang HL, Gu JF, Li LY and
Liu XY: VEGI-armed oncolytic adenovirus inhibits tumor
neovascularization and directly induces mitochondria-mediated
cancer cell apoptosis. Cell Res. 20:367–378. 2010. View Article : Google Scholar
|
|
31
|
Mück C, Herndler-Brandstetter D, Micutkova
L, Grubeck-Loebenstein B and Jansen-Dürr P: Two functionally
distinct isoforms of TL1A (TNFSF15) generated by differential
ectodomain shedding. J Gerontol A Biol Sci Med Sci. 65:1165–1180.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamanegi K, Yamane J, Kobayashi K, et al:
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid
plays a role in inhibiting the shedding of MHC class I-related
molecules A and B on the surface of human osteosarcoma cells. Oncol
Rep. 28:1585–1590. 2012.PubMed/NCBI
|
